Viatris vs Grafana Labs

Side-by-side comparison of AI visibility scores, market position, and capabilities

Viatris leads in AI visibility (88 vs 45)
Viatris logo

Viatris

LeaderHealthcare Tech

Generic Pharmaceuticals

Viatris (VTRS) reported ~$15.4B revenue in FY2024. Global generic and specialty pharmaceutical company formed by Pfizer's Upjohn spinoff merging with Mylan. HQ: Canonsburg, PA.

AI VisibilityBeta
Overall Score
A88
Category Rank
#1 of 1
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
98
Perplexity
98
Gemini
88

About

Viatris Inc. is a global pharmaceutical company formed in 2020 through the combination of Pfizer's off-patent branded drug unit (Upjohn) and Mylan, one of the world's largest generic drug manufacturers. The company manufactures, licenses, and distributes approximately 1,400 approved molecules across branded generics, complex generics, and a portfolio of iconic off-patent brands including Lipitor (atorvastatin), Viagra (sildenafil), EpiPen, and Xanax (alprazolam) sold in markets where these brands retain meaningful recognition and premium pricing.

Full profile
Grafana Labs logo

Grafana Labs

ChallengerIT Operations & Observability

Metrics Visualization

Open-source observability leader with $6B valuation; Grafana dashboards plus Loki/Tempo/Mimir stack serving millions of installations as Datadog alternative with community-driven adoption.

AI VisibilityBeta
Overall Score
C45
Category Rank
#1 of 1
AI Consensus
62%
Trend
down
Per Platform
ChatGPT
46
Perplexity
41
Gemini
36

About

Grafana Labs is the company behind Grafana — the world's most widely used open-source observability and data visualization platform — providing the Grafana Cloud managed service, Grafana Enterprise, and a suite of open-source tools including Loki (log aggregation), Tempo (distributed tracing), and Mimir (long-term Prometheus metrics storage). Founded in 2019 by Raj Dutt, Torkel Ödegaard, and Tom Wilkie (the creators of the original Grafana open-source project) in New York, Grafana Labs has raised over $600 million at a $6 billion valuation.\n\nGrafana's open-source project — downloadable and self-hostable for free — has driven extraordinary community adoption: millions of Grafana installations globally power engineering, IoT, and business dashboards at organizations from startups to large enterprises. Grafana's plugin ecosystem connects to 200+ data sources (Prometheus, InfluxDB, Elasticsearch, AWS CloudWatch, databases), making it the universal observability visualization layer. Grafana Cloud packages the open-source tools into a fully managed SaaS offering with unlimited metrics, logs, traces, and dashboards.\n\nIn 2025, Grafana Labs competes in the observability platform market against Datadog, New Relic, Dynatrace, and the ELK/OpenSearch stack for enterprise monitoring and observability. Grafana's open-source-first model creates a moat through developer community and ecosystem — engineers who build personal dashboards on Grafana become advocates for Grafana Cloud at their employers. The company's OpenTelemetry alignment and multi-source data philosophy ("query any data, anywhere") differentiates it from Datadog's monolithic agent model. The 2025 strategy focuses on growing Grafana Cloud enterprise adoption, advancing AI-powered Sift (automatic anomaly investigation), and expanding the Grafana IRM (incident response management) product.

Full profile

AI Visibility Head-to-Head

88
Overall Score
45
#1
Category Rank
#1
58
AI Consensus
62
stable
Trend
down
98
ChatGPT
46
98
Perplexity
41
88
Gemini
36
88
Claude
53
82
Grok
46

Key Details

Category
Generic Pharmaceuticals
Metrics Visualization
Tier
Leader
Challenger
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Viatris
Generic Pharmaceuticals
Only Grafana Labs
Metrics Visualization

Integrations

Only Viatris
Only Grafana Labs
Viatris is classified as company (part of Pfizer). Grafana Labs is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.